EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.

I Davis, A Long, S Yip, D Espinoza, J Thompson, Ganessan Kichenadasse, M Harrison, R Lowenthal, N. Pavlakis, A Azad, G Kannourakis, C Steer, D Goldstein, Jeremy Shapiro, Rozelle Harvie, L Jovanovic, A Hudson, Colleen Nelson, Martin Stockler, A Martin

    Research output: Contribution to journalArticlepeer-review

    12 Citations (Scopus)

    Fingerprint Dive into the research topics of 'EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma.'. Together they form a unique fingerprint.

    Medicine & Life Sciences